From Cobenfy to Emraclidine: the muscarinic path to safer antipsychotics
Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.
IFLScience on MSN10d
Newly Approved Schizophrenia Drug Could Eventually Treat Alzeimer’s-Related Psychosis
A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...
Medscape3d
New Pharmacologic and Minimally Invasive Therapies for the Overactive Bladder
Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor subtype), and they thereby inhibit involuntary bladder contractions. [19] The effective ...
Kaleido Scope6y
Christianne Strang
Research and Teaching Interests: The expression and function of acetylcholine receptors in the retina, retinal anatomy, retinal development, developmental neuroscience, behavioral neuroscience ...
MedCity News1mon
AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test
which are receptors in the central nervous system that play key roles in neuronal functions. Emraclidine is an agonist of the muscarinic acetylcholine receptor type 4, or M4 receptor. By ...